Literature DB >> 10836297

Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients.

L Bubendorf1, A Schöpfer, U Wagner, G Sauter, H Moch, N Willi, T C Gasser, M J Mihatsch.   

Abstract

The prognosis of prostate cancer is mainly determined by the presence or absence of metastases. Nevertheless, the metastatic pathways in prostate cancer are not entirely understood. Among 19,316 routine autopsies performed from 1967 to 1995 on men older than 40 years of age, the reports from those 1,589 (8.2%) with prostate cancer were analyzed. Hematogeneous metastases were present in 35% of 1,589 patients with prostate cancer, with most frequent involvement being bone (90%), lung (46%), liver (25%), pleura (21%), and adrenals (13%). Several lines of evidence suggested the existence of a backward metastatic pathway through veins from the prostate to the spine in addition to classical hematogeneous tumor spread via the vena cava. First, there was an inverse relationship between spine and lung metastases, suggesting that metastasis to the spine is independent of lung metastasis. Second, the maximum frequency of spine involvement occurred in smaller tumors (4 to 6 cm) as compared with the maximum spread to lung (6 to 8 cm) and liver (>8 cm), suggesting that spine metastases precede lung and liver metastases in many prostate cancers. Third, there was a gradual decrease in spine involvement from the lumbar to the cervical level (97% v 38%), which is consistent with a subsequent upward metastatic spread along spinal veins after initial lumbar metastasis. The results of this study show that bone, lung, and liver are the most frequent sites of distant prostate cancer metastases. Besides the cava-type of metastasis through lung passage, there are strong arguments for the existence and clinical significance of a backward venous spread to the spine, which is likely to occur early in the metastatic process.

Entities:  

Mesh:

Year:  2000        PMID: 10836297     DOI: 10.1053/hp.2000.6698

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  545 in total

1.  Prostate cancer in bone: importance of context for inhibition of matrix metalloproteinases.

Authors:  Mina J Bissell; Johanne Le Beyec; Robin L Anderson
Journal:  J Natl Cancer Inst       Date:  2002-01-02       Impact factor: 13.506

2.  Comparison of hybrid 68Ga-PSMA-PET/CT and 99mTc-DPD-SPECT/CT for the detection of bone metastases in prostate cancer patients: Additional value of morphologic information from low dose CT.

Authors:  Jan-Carlo Janssen; Sebastian Meißner; Nadine Woythal; Vikas Prasad; Winfried Brenner; Gerd Diederichs; Bernd Hamm; Marcus R Makowski
Journal:  Eur Radiol       Date:  2017-08-04       Impact factor: 5.315

3.  Optimization of PSA screening policies: a comparison of the patient and societal perspectives.

Authors:  Jingyu Zhang; Brian T Denton; Hari Balasubramanian; Nilay D Shah; Brant A Inman
Journal:  Med Decis Making       Date:  2011-09-20       Impact factor: 2.583

4.  [Castration-resistant prostate cancer: surgical and radio-oncological therapeutic options].

Authors:  S Preusser; P M Putora; L Plasswilm; H P Schmid
Journal:  Urologe A       Date:  2012-01       Impact factor: 0.639

5.  Painful testicular metastasis from prostate adenocarcinoma.

Authors:  Karla A Lee; Erik Mayer; Vincent Khoo
Journal:  BMJ Case Rep       Date:  2017-12-05

6.  YKL-40 promotes the migration and invasion of prostate cancer cells by regulating epithelial mesenchymal transition.

Authors:  Hailong Hao; Lei Wang; Huiqing Chen; Liwu Xie; Tao Bai; Hongyu Liu; Dongwen Wang
Journal:  Am J Transl Res       Date:  2017-08-15       Impact factor: 4.060

Review 7.  Genetics of metastasis: melanoma and other cancers.

Authors:  Noel Turner; Olivia Ware; Marcus Bosenberg
Journal:  Clin Exp Metastasis       Date:  2018-05-02       Impact factor: 5.150

8.  Prostate cancer with an unusual metastatic affinity for the appendix, inducing acute appendicitis.

Authors:  Erasmia Christou
Journal:  BMJ Case Rep       Date:  2018-03-20

Review 9.  Targeted α-particle therapy of bone metastases in prostate cancer.

Authors:  Hossein Jadvar; David I Quinn
Journal:  Clin Nucl Med       Date:  2013-12       Impact factor: 7.794

10.  Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time.

Authors:  Matthew R Smith; Fred Saad; Stephane Oudard; Neal Shore; Karim Fizazi; Paul Sieber; Bertrand Tombal; Ronaldo Damiao; Gavin Marx; Kurt Miller; Peter Van Veldhuizen; Juan Morote; Zhishen Ye; Roger Dansey; Carsten Goessl
Journal:  J Clin Oncol       Date:  2013-09-16       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.